Literature DB >> 26405039

Role of a Hydrophobic Pocket in Polyamine Interactions with the Polyspecific Organic Cation Transporter OCT3.

Dan C Li1, Colin G Nichols1, Monica Sala-Rabanal2.   

Abstract

Organic cation transporter 3 (OCT3, SLC22A3) is a polyspecific, facilitative transporter expressed in astrocytes and in placental, intestinal, and blood-brain barrier epithelia, and thus elucidating the molecular mechanisms underlying OCT3 substrate recognition is critical for the rational design of drugs targeting these tissues. The pharmacology of OCT3 is distinct from that of other OCTs, and here we investigated the role of a hydrophobic cavity tucked within the translocation pathway in OCT3 transport properties. Replacement of an absolutely conserved Asp by charge reversal (D478E), neutralization (D478N), or even exchange (D478E) abolished MPP(+) uptake, demonstrating this residue to be obligatory for OCT3-mediated transport. Mutations at non-conserved residues lining the putative binding pocket of OCT3 to the corresponding residue in OCT1 (L166F, F450L, and E451Q) reduced the rate of MPP(+) transport, but recapitulated the higher sensitivity pharmacological profile of OCT1. Thus, interactions of natural polyamines (putrescine, spermidine, spermine) and polyamine-like potent OCT1 blockers (1,10-diaminodecane, decamethonium, bistriethylaminodecane, and 1,10-bisquinuclidinedecane) with wild-type OCT3 were weak, but were significantly potentiated in the mutant OCT3s. Conversely, a reciprocal mutation in OCT1 (F161L) shifted the polyamine-sensitivity phenotype toward that of OCT3. Further analysis indicated that OCT1 and OCT3 can recognize essentially the same substrates, but the strength of substrate-transporter interactions is weaker in OCT3, as informed by the distinct makeup of the hydrophobic cleft. The residues identified here are key contributors to both the observed differences between OCT3 and OCT1 and to the mechanisms of substrate recognition by OCTs in general.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  OCT3; SLC22A3; membrane transport; mutagenesis; organic cation transporter; pharmacology; polyamine; rational drug design; structure-function

Mesh:

Substances:

Year:  2015        PMID: 26405039      PMCID: PMC4646014          DOI: 10.1074/jbc.M115.668913

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  47 in total

1.  Complex rectification of Müller cell Kir currents.

Authors:  Yuriy V Kucheryavykh; Yaroslav M Shuba; Sergei M Antonov; Mikhail Y Inyushin; Luis Cubano; Wade L Pearson; Harley Kurata; Andreas Reichenbach; Rüdiger W Veh; Colin G Nichols; Misty J Eaton; Serguei N Skatchkov
Journal:  Glia       Date:  2008-05       Impact factor: 7.452

2.  Epilepsy, ataxia, sensorineural deafness, tubulopathy, and KCNJ10 mutations.

Authors:  Detlef Bockenhauer; Sally Feather; Horia C Stanescu; Sascha Bandulik; Anselm A Zdebik; Markus Reichold; Jonathan Tobin; Evelyn Lieberer; Christina Sterner; Guida Landoure; Ruchi Arora; Tony Sirimanna; Dorothy Thompson; J Helen Cross; William van't Hoff; Omar Al Masri; Kjell Tullus; Stella Yeung; Yair Anikster; Enriko Klootwijk; Mike Hubank; Michael J Dillon; Dirk Heitzmann; Mauricio Arcos-Burgos; Mark A Knepper; Angus Dobbie; William A Gahl; Richard Warth; Eamonn Sheridan; Robert Kleta
Journal:  N Engl J Med       Date:  2009-05-07       Impact factor: 91.245

Review 3.  Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences.

Authors:  Min-Koo Choi; Im-Sook Song
Journal:  Drug Metab Pharmacokinet       Date:  2008       Impact factor: 3.614

4.  Molecular determinants of substrate/inhibitor binding to the human and rabbit renal organic cation transporters hOCT2 and rbOCT2.

Authors:  Wendy M Suhre; Sean Ekins; Cheng Chang; Peter W Swaan; Stephen H Wright
Journal:  Mol Pharmacol       Date:  2005-01-03       Impact factor: 4.436

5.  Seizures, sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance (SeSAME syndrome) caused by mutations in KCNJ10.

Authors:  Ute I Scholl; Murim Choi; Tiewen Liu; Vincent T Ramaekers; Martin G Häusler; Joanne Grimmer; Sheldon W Tobe; Anita Farhi; Carol Nelson-Williams; Richard P Lifton
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-16       Impact factor: 11.205

6.  Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.

Authors:  Gustav Ahlin; Johan Karlsson; Jenny M Pedersen; Lena Gustavsson; Rolf Larsson; Pär Matsson; Ulf Norinder; Christel A S Bergström; Per Artursson
Journal:  J Med Chem       Date:  2008-09-13       Impact factor: 7.446

Review 7.  Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases.

Authors:  Robert A Casero; Laurence J Marton
Journal:  Nat Rev Drug Discov       Date:  2007-05       Impact factor: 84.694

8.  High-affinity cation binding to organic cation transporter 1 induces movement of helix 11 and blocks transport after mutations in a modeled interaction domain between two helices.

Authors:  Dmitry Gorbunov; Valentin Gorboulev; Natalia Shatskaya; Thomas Mueller; Ernst Bamberg; Thomas Friedrich; Hermann Koepsell
Journal:  Mol Pharmacol       Date:  2007-10-16       Impact factor: 4.436

9.  The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway.

Authors:  Mei Cui; Radha Aras; Whitney V Christian; Phillip M Rappold; Mamata Hatwar; Joseph Panza; Vernice Jackson-Lewis; Jonathan A Javitch; Nazzareno Ballatori; Serge Przedborski; Kim Tieu
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-29       Impact factor: 11.205

10.  Structural determinants of inhibitor interaction with the human organic cation transporter OCT2 (SLC22A2).

Authors:  Oliver Zolk; Thomas F Solbach; Jörg König; Martin F Fromm
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-11-11       Impact factor: 3.000

View more
  3 in total

1.  CDER167, a dual inhibitor of URAT1 and GLUT9, is a novel and potent uricosuric candidate for the treatment of hyperuricemia.

Authors:  Ze-An Zhao; Yu Jiang; Yan-Yu Chen; Ting Wu; Qun-Sheng Lan; Yong-Mei Li; Lu Li; Yang Yang; Cui-Ting Lin; Ying Cao; Ping-Zheng Zhou; Jia-Yin Guo; Yuan-Xin Tian; Jian-Xin Pang
Journal:  Acta Pharmacol Sin       Date:  2021-03-25       Impact factor: 6.150

2.  Uptake of Biotinylated Spermine in Astrocytes: Effect of Cx43 siRNA, HIV-Tat Protein and Polyamine Transport Inhibitor on Polyamine Uptake.

Authors:  Christian J Malpica-Nieves; Yomarie Rivera; David E Rivera-Aponte; Otto Phanstiel; Rüdiger W Veh; Misty J Eaton; Serguei N Skatchkov
Journal:  Biomolecules       Date:  2021-08-11

Review 3.  Astrocytes as Perspective Targets of Exercise- and Caloric Restriction-Mimetics.

Authors:  Ulyana Lalo; Yuriy Pankratov
Journal:  Neurochem Res       Date:  2021-03-07       Impact factor: 3.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.